ArticleCureus2025
Exploring the Relationship Between Atherogenic Index of Plasma, Body Mass Index, and Fatty Liver in Obese Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Atherogenic index of plasma as a simple marker for NAFLD risk stratification in community-dwelling older adults: a cross-sectional study with incremental predictive value assessment.Frontiers in endocrinology · 2026Article
- Article
- Fasting blood glucose to high-density lipoprotein cholesterol ratio and MASLD risk: non-linear association and BMI mediation in non-diabetic adults.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to estimate the body mass index (BMI) and the atherogenic index of plasma (AIP) in obese individuals, evaluate the grade of fatty liver using abdominal ultrasound, and assess the relationships among AIP, BMI, and fatty liver severity. METHODOLOGY: This hospital-based cross-sectional study was conducted at R.L. Jalappa Hospital and Research Centre in Kolar to examine the association between three key metabolic parameters - AIP, BMI, and ultrasound-diagnosed fatty liver - in obese individuals. The study was carried out over three months from December 2024 to February 2025 and included 26 adults with a BMI greater than 25 kg/m² based on the Asian cut-off values. Participants underwent BMI calculation, fasting lipid profile testing, and abdominal ultrasound for fatty liver grading. Individuals with chronic liver disease, alcohol use, or conditions affecting lipid metabolism were excluded. AIP was calculated using the established logarithmic formula: log (triglycerides (TG)/high-density lipoprotein cholesterol (HDL-C)). Statistical analysis was performed using IBM SPSS Statistics v22 (IBM Corp., Armonk, USA), with a p-value less than 0.05 considered statistically significant.
resultsIn this study, 18 (69.2%) participants were classified as obese (BMI ≥30 kg/m²), and the most common fatty liver grade was Grade II, observed in 11 (42.3%) patients. A total of 17 (65.4%) patients had moderate to severe fatty liver (Grades II and III). High AIP values (>0.21) were observed in 16 (61.5%) patients, with 23 (88.4%) showing elevated atherogenic risk. AIP levels significantly increased with fatty liver severity (p<0.05), and the mean BMI also rose progressively across fatty liver grades (p<0.05). These findings highlight strong associations between BMI, AIP, and fatty liver severity in obese individuals.
conclusionThe results demonstrated a clear positive correlation between both BMI and AIP values and the severity of fatty liver disease in the obese population. These findings suggest that BMI and AIP are practical, cost-effective screening tools for the early detection of metabolic dysfunction-associated steatotic liver disease (MASLD). Their utility is particularly relevant in clinical settings with limited access to advanced diagnostic modalities. The study supports the integration of BMI and AIP into routine screening protocols to guide early intervention and mitigate the long-term health burden of non-alcoholic fatty liver disease (NAFLD).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.